Tumorigenesis and the angiogenic switch

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219 · see citing works

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885 · see citing works

Genetic Alterations during Colorectal-Tumor Development

Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704 · see citing works

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617 · see citing works

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · see citing works

Tumors: Wounds That Do Not Heal

Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · see citing works

Mechanisms of angiogenesis and arteriogenesis

Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,146 · see citing works

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981 · see citing works

Vascular-specific growth factors and blood vessel formation

Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · see citing works

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · see citing works

Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF

Holash, J. A., Maisonpierre, P. C., Compton, D. L., Boland, P., Alexander, C., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,181 · see citing works

Induction of angiogenesis during the transition from hyperplasia to neoplasia

Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879 · see citing works

Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860 · see citing works

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions

Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., Mol, M. D., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,673 · see citing works

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,542 · see citing works

VEGF and the quest for tumour angiogenesis factors

Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536 · see citing works

Clinical translation of angiogenesis inhibitors

Kerbel, R. S., & Folkman, J. (2002) · Nature reviews. Cancer · doi:10.1038/nrc905 · Cited by 1,513 · see citing works

Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1

Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,437 · see citing works

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361 · see citing works

A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF

Benjamin, L. E., Hemo, I., & Keshet, E. (1998) · Development · doi:10.1242/dev.125.9.1591 · Cited by 1,265 · see citing works

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,234 · see citing works

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192 · see citing works

c-MYC: more than just a matter of life and death

Pelengaris, S., Khan, M., & Evan, G. I. (2002) · Nature reviews. Cancer · doi:10.1038/nrc904 · Cited by 1,172 · see citing works

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Klement, G. L., Baruchel, S., Rak, J. W., Man, S., Clark, K., Hicklin, D. J., Böhlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,166 · see citing works

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

Ravi, R. K., Mookerjee, B., Bhujwalla, Z. M., Sutter, T. R., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · PubMed Central · Cited by 1,099 · see citing works

HIF-1 and tumor progression: pathophysiology and therapeutics

Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060 · see citing works

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,032 · see citing works

Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia

Stone, J., Itin, A., Alon, T., Pe'er, J., Gnessin, H., Chan‐Ling, T., & Keshet, E. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-07-04738.1995 · Cited by 1,004 · see citing works

Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice

Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988 · see citing works

Abnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors

Morikawa, S., Bałuk, P., Kaidoh, T., Haskell, A., Jain, R. K., & McDonald, D. M. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64920-6 · Cited by 987 · see citing works

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α

Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967 · see citing works

Rules for Making Human Tumor Cells

Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951 · see citing works

Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis

Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G. H., & Hanahan, D. (1999) · Genes & Development · doi:10.1101/gad.13.11.1382 · Cited by 946 · cited 1× · see citing works

Mechanisms of normal and tumor-derived angiogenesis

Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809 · see citing works

Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I

Zhou, Z., Apte, S., Soininen, R., Cao, R., Baaklini, G. Y., Rauser, R. W., Wang, J., Cao, Y., & Tryggvason, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.060037197 · Cited by 791 · see citing works

Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us

Hlatky, L. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.12.883 · Cited by 780 · see citing works

Pericytes in the microvasculature

Hirschi, K. K., & D'Amore, P. A. (1996) · Cardiovascular Research · doi:10.1016/s0008-6363(96)00063-6 · Cited by 763 · see citing works

Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.

Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 746 · see citing works

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF

Holash, J. A., Wiegand, S. J., & Yancopoulos, G. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203035 · Cited by 738 · see citing works

Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells

Hattori, K., Dias, S., Heissig, B., Hackett, N. R., Lyden, D. C., Tateno, M., Hicklin, D. J., Zhu, Z., Witte, L., Crystal, R. G., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.9.1005 · Cited by 685 · see citing works

Vasculogenic Mimicry and Tumor Angiogenesis

Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 682 · see citing works

Cyclooxygenase 2: a molecular target for cancer prevention and treatment

Subbaramaiah, K., & Dannenberg, A. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00043-3 · Cited by 650 · see citing works

Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment

Hattori, K., Heissig, B., Wu, Y. L., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Böhlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 632 · see citing works

Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression

Pelengaris, S., Khan, M., & Evan, G. I. (2002) · Cell · doi:10.1016/s0092-8674(02)00738-9 · Cited by 623 · see citing works

Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy

Black, W. C., & Welch, H. G. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304293281706 · Cited by 547 · see citing works

Angiostatin binds ATP synthase on the surface of human endothelial cells

Moser, T. L., Stack, M. S., Asplin, I. R., Enghild, J. J., Højrup, P., Everitt, L., Hubchak, S. C., Schnaper, H. W., & Pizzo, S. V. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2811 · Cited by 526 · see citing works

Issues and progress with protein kinase inhibitors for cancer treatment

Dancey, J. E., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 524 · see citing works

Anti-VEGF Antibody Treatment of Glioblastoma Prolongs Survival But Results in Increased Vascular Cooption

Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900102 · Cited by 510 · see citing works

Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal

Benjamin, L. E., & Keshet, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8761 · Cited by 507 · see citing works

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 496 · see citing works

Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor

Rodrı́guez-Manzaneque, J. C., Lane, T. F., Ortega, M.-A., Hynes, R. O., Lawler, J., & Iruela‐Arispe, M. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171460498 · Cited by 473 · see citing works

Canstatin, a Novel Matrix-derived Inhibitor of Angiogenesis and Tumor Growth

Kamphaus, G. D., Colorado, P. C., Panka, D. J., Hopfer, H., Ramchandran, R., de la Torre, A., Maeshima, Y., Mier, J. W., Sukhatme, V. P., & Kalluri, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.2.1209 · Cited by 470 · see citing works

Stabilization of Vascular Endothelial Growth Factor mRNA by Hypoxia and Hypoglycemia and Coregulation with Other Ischemia-Induced Genes

Stein, I., Neeman, M., Shweiki, D., Itin, A., & Keshet, E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5363 · Cited by 455 · see citing works

A role for survivin in chemoresistance of endothelial cells mediated by VEGF

Tran, J., Master, Z., Yu, J., Rak, J. W., Dumont, D., & Kerbel, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072586399 · Cited by 435 · see citing works

Activation of the HIF pathway in cancer

Maxwell, P. H. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00193-3 · Cited by 426 · see citing works

Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

Yu, J., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426 · see citing works

Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.

Papapetropoulos, A., García‐Cardeña, G., Dengler, T. J., Maisonpierre, P. C., Yancopoulos, G. D., & Sessa, W. C. (1999) · PubMed · Cited by 418 · see citing works

Tumor Angiogenesis: A Quantitative Method for Histologic Grading 2

Brem, S. S., Cotran, R. S., & Folkman, J. (1972) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/48.2.347 · Cited by 415 · see citing works

Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor

Pettersson, A. F., Nagy, J. A., Brown, L. F., Sundberg, C., Morgan, E. S., Jungles, S., Carter, R., Krieger, J. E., Manseau, E. J., Harvey, V. S., et al. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780013 · Cited by 412 · see citing works

Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression.

Mukhopadhyay, D., Tsiokas, L., & Sukhatme, V. P. (1995) · PubMed · Cited by 404 · see citing works

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis

Inoue, M., Hager, J. H., Ferrara, N., Gerber, H., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380 · see citing works

Angiomotin

Troyanovsky, B., Levchenko, T., Månsson, G., Matvijenko, O., & Holmgren, L. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.6.1247 · Cited by 378 · see citing works

Inhibition of Cyclooxygenase-2 Gene Expression by p53

Subbaramaiah, K., Altorki, N. K., Chung, W. J., MESTRE, J. R., Sampat, A., & Dannenberg, A. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10911 · Cited by 350 · see citing works

Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis.

Weinstat‐Saslow, D., Zabrenetzky, V. S., VanHoutte, K., Frazier, W. A., Roberts, D. D., & Steeg, P. S. (1994) · PubMed · Cited by 348 · see citing works

Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo

Brantley, D. M., Cheng, N., Thompson, E. J., Lin, Q. F., Brekken, R. A., Thorpe, P. E., Muraoka, R. S., Cerretti, D. P., Pozzi, A., Jackson, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205679 · Cited by 314 · see citing works

A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis

Nishimori, H., Shiratsuchi, T., Urano, T., Kimura, Y., Kiyono, K., Tatsumi, K., Yoshida, S., Ono, M., Kuwano, M., Nakamura, Y., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1201542 · Cited by 293 · see citing works

Transcriptional Activation by p53 of the Human Type IV Collagenase (Gelatinase A or Matrix Metalloproteinase 2) Promoter

Bian, J., & Sun, Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6330 · Cited by 274 · see citing works

Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.

Cheng, N., Brantley, D. M., Liu, H., Lin, Q., Enriquez, M., Gale, N., Yancopoulos, G. D., Cerretti, D. P., Daniel, T. O., & Chen, J. (2002) · PubMed · Cited by 252 · see citing works

Lysophosphatidic Acid Induction of Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells

Hu, Y., Tee, M. K., Goetzl, E. J., Auersperg, N., Mills, G. B., Ferrara, N., & Jaffe, R. B. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.10.762 · Cited by 246 · see citing works

Cyclooxygenase-2 and prostate carcinogenesis

Hussain, T., Gupta, S., & Mukhtar, H. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00524-4 · Cited by 239 · see citing works

Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis

Dor, Y., Porat, R. M., & Keshet, E. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1367 · Cited by 237 · see citing works

Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.

Zhang, L., Yu, D., Hu, M., Xiong, S., Lang, A., Ellis, L. M., & Pollock, R. E. (2000) · PubMed · Cited by 230 · see citing works

Identification of the Anti-angiogenic Site within Vascular Basement Membrane-derived Tumstatin

Maeshima, Y., Manfredi, M. G., Reimer, C., Holthaus, K. A., Hopfer, H., Chandamuri, B. R., Kharbanda, S. M., & Kalluri, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007764200 · Cited by 229 · see citing works

Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2

Vajkoczy, P., Farhadi, M. R., Gaumann, A. K. A., Heidenreich, R., Erber, R., Wunder, A., Tonn, J. C., Menger, M. D., & Breier, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14105 · Cited by 219 · see citing works

Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines

Zabrenetzky, V. S., Harris, C. C., Steeg, P. S., & Roberts, D. D. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590209 · Cited by 219 · see citing works

Placental growth factor is a survival factor for tumor endothelial cells and macrophages.

Adini, A., Kornaga, T., Firoozbakht, F., & Benjamin, L. E. (2002) · PubMed · Cited by 212 · see citing works

Cyclooxygenase-2: a therapeutic target in angiogenesis

Iñiguez, M. A., Rodrı́guez, A., Volpert, O. V., Fresno, M., & Redondo, J. M. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)00011-4 · Cited by 204 · see citing works

Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation

Lynch, C. A., Tycko, B., Bestor, T. H., & Walsh, C. P. (2002) · Molecular Cancer · doi:10.1186/1476-4598-1-2 · Cited by 202 · see citing works

Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma.

Pal, S., Datta, K., & Mukhopadhyay, D. (2001) · PubMed · Cited by 197 · see citing works

Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis.

Elson, D. A., Riley, R. R., Lacey, A., Thórdarson, G., Talamantes, F. J., & Arbeit, J. M. (2000) · PubMed · Cited by 187 · see citing works

Vasculogenic Mimicry: How Convincing, How Novel, and How Significant?

McDonald, D. M., Munn, L. L., & Jain, R. K. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64740-2 · Cited by 187 · see citing works

Response of tumour cells to hypoxia: role of p53 and NFkB.

Royds, J. A., Dower, S., Qwarnström, E. E., & Lewis, C. E. (1998) · Molecular Pathology · doi:10.1136/mp.51.2.55 · Cited by 182 · see citing works

Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2

Vajkoczy, P., Farhadi, M. R., Gaumann, A. K. A., Heidenreich, R., Erber, R., Wunder, A., Tonn, J. C., Menger, M. D., & Breier, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214105 · Cited by 182 · see citing works

Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors

Rafii, S., Heissig, B., & Hattori, K. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301723 · Cited by 175 · see citing works

Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis

Dohn, M. R., Jiang, J., & Chen, X. (2001) · Oncogene · doi:10.1038/sj.onc.1204816 · Cited by 146 · see citing works

How aneuploidy may cause cancer and genetic instability.

DUESBERG, P. H., Rasnick, D., Li, R., Winters, L. N., Rausch, C., & Hehlmann, R. (1999) · PubMed · Cited by 135 · see citing works

The antiangiogenic agent TNP-470 requires p53 and p21 CIP/WAF for endothelial cell growth arrest

Yeh, J.-R. J., Mohan, R., & Crews, C. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.23.12782 · Cited by 120 · see citing works

Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.

OʼReilly, M. (1997) · PubMed · Cited by 115 · see citing works

Thrombospondin-1 Gene Expression Affects Survival and Tumor Spectrum of p53-Deficient Mice

Lawler, J., Miao, W., Duquette, M. A., Bouck, N., Bronson, R. T., & Hynes, R. O. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63042-8 · Cited by 115 · see citing works

Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor.

Laderoute, K. R., Alarcon, R. M., Brody, M. D., Calaoagan, J. M., Chen, E. Y., Knapp, A. M., Yun, Z., Denko, N. C., & Giaccia, A. J. (2000) · PubMed · Cited by 107 · see citing works

The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression

Volpert, O. V., Stellmach, V., & BOUCK, N. P. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666034 · Cited by 105 · see citing works

In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effectsPreprint

Filleur, S., Volpert, O. V., Degeorges, A., Voland, C., Reiher, F., Clézardin, P., Bouck, N., & Cabon, F. (2001) · Genes & Development · doi:10.1101/gad.193501 · Cited by 103 · see citing works

The Significance of Atypia and Histologic Malignancy in Pilocytic Astrocytoma of the Cerebellum: A Clinicopathologic and Flow Cytometric Study

Tomlinson, F. H., Scheithauer, B. W., Hayostek, C. J., Parisi, J. E., Meyer, F. B., Shaw, E. G., Weiland, T. L., Katzmann, J. A., & Jack, C. R. (1994) · Journal of Child Neurology · doi:10.1177/088307389400900317 · Cited by 102 · see citing works

Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis

Bergers, G., Hanahan, D., & Coussens, L. M. (1998) · The International Journal of Developmental Biology · doi:10.1387/ijdb.9853830 · Cited by 89 · see citing works

Thrombospondin‐1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia

Kwak, C. H., Jin, R., Lee, C. H., Park, M. S., & Lee, S. E. (2002) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.01417.x · Cited by 75 · see citing works

The development of epithelial phenotypes in the human fetal and infant breast

Anbazhagan, R., Osin, P., Bártková, J., Nathan, B., Lane, E. B., & Gusterson, B. A. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199802)184:2 · Cited by 73 · see citing works

Aerosol delivery of PEI–p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis

Gautam, A. K., Densmore, C. L., Melton, S., Golunski, E., & Waldrep, J. C. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700405 · Cited by 71 · see citing works

Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12.

Gee, M. S., Koch, C. J., Evans, S. M., Jenkins, W. T., Pletcher, C. H., Moore, J. S., Koblish, H. K., Lee, J. J., Lord, E. M., Trinchieri, G., et al. (1999) · PubMed · Cited by 71 · see citing works

Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents.

Joseph, I. B. J., Vukanovic, J., & Isaacs, J. T. (1996) · PubMed · Cited by 56 · see citing works

p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma

Holmgren, L., Jackson, G., & Arbiser, J. L. (1998) · Oncogene · doi:10.1038/sj.onc.1201993 · Cited by 54 · see citing works

Chemoprevention of Prostate Cancer: Current Status and Future Directions

Lieberman, R. (2002) · Cancer and Metastasis Reviews · doi:10.1023/a:1021267128567 · Cited by 47 · see citing works

High cyclooxygenase-2 expression in cervical adenocarcinomas

Chen, Y., Wang, L.-S., Wang, P., Lai, C.-R. U., Yen, M.-S., Ng, H., & Yuan, C. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00066-5 · Cited by 46 · see citing works

p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene.

Agani, F. H., Kirsch, D. G., Friedman, S. L., Kastan, M. B., & Semenza, G. L. (1997) · PubMed · Cited by 37 · see citing works

Hypoxia upregulates Bcl‐2 expression and suppresses interferon‐γ induced antiangiogenic activity in human tumor derived endothelial cells

Wang, J. H., Wu, Q. D., Bouchier-Hayes, D., & Redmond, H. P. (2002) · Cancer · doi:10.1002/cncr.10520 · Cited by 33 · see citing works

Combining Antiangiogenic Agents with Metronomic Chemotherapy Enhances Efficacy against Late-stage Pancreatic Islet Carcinomas in MicePreprint

Bergers, G., & Hanahan, D. (2002) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2002.67.293 · Cited by 29 · see citing works

Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling.

Cline, E. I., Bicciato, S., DiBello, C., & Lingen, M. W. (2002) · PubMed · Cited by 28 · see citing works

Human Metalloproteinase‐1 (Collagenase‐1) Is a Tumor Suppressor Protein p53 Target Gene

Sun, Y., Sun, Y., Wenger, L., Rutter, J. L., Brinckerhoff, C., & Cheung, H. S. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07749.x · Cited by 15 · see citing works

Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165.

Zhang, X., Zhu, X., Gao, J., Qian, C., Kuang, Z.-J., Liu, Z., & Zeng, Y. (2001) · PubMed · Cited by 13 · see citing works

Renal cell carcinoma may adapt to and overcome anti‐angiogenic intervention with thalidomide

Douglas, M. L., Reid, J. L., Hii, S.-I., Jonsson, J. R., & Nicol, D. L. (2002) · British Journal of Urology · doi:10.1046/j.1464-410x.2002.02666.x · Cited by 10 · see citing works

Anti-angiogenic drug AGM1470 suppresses smooth muscle cell migration induced by endothelial PDGF

Shigematsu, K., Yasuhara, H., Shigematsu, H., & Muto, T. (1997) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/s1078-5884(97)80241-9 · Cited by 5 · see citing works

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Oxidative stress, inflammation, and cancer: How are they linked?

Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441 · see citing works

Vascular Endothelial Growth Factor: Basic Science and Clinical Progress

Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,707 · see citing works

To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery

Danhier, F., Féron, O., & Véronique Préat, A. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,827 · see citing works

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · see citing works

Concepts of extracellular matrix remodelling in tumour progression and metastasis

Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296 · see citing works

Engineered Nanoparticles for Drug Delivery in Cancer Therapy

Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164 · see citing works

Targeting macrophages: therapeutic approaches in cancer

Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,057 · see citing works

The extracellular matrix modulates the hallmarks of cancer

Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO Reports · doi:10.15252/embr.201439246 · Cited by 2,014 · see citing works

Tumor microenvironment as a therapeutic target in cancer

Xiao, Y. Q., & Yu, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,977 · see citing works

Matrix metalloproteinases and tumor metastasis

Deryugina, E. I., & Quigley, J. P. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7886-9 · Cited by 1,960 · see citing works

Microenvironmental regulation of tumour angiogenesis

De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847 · see citing works

VEGF as a Key Mediator of Angiogenesis in Cancer

Carmeliet, P. (2005) · Oncology · doi:10.1159/000088478 · Cited by 1,776 · see citing works

Friends or foes — bipolar effects of the tumour stroma in cancer

Mueller, M. M., & Fusenig, N. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1477 · Cited by 1,757 · see citing works

Models, mechanisms and clinical evidence for cancer dormancy

Aguirre‐Ghiso, J. A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2256 · Cited by 1,673 · see citing works

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V. A., Hirsh, V., Leighl, N. B., Mezger, J. M., Archer, V. R., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,500 · see citing works

The role of pericytes in blood-vessel formation and maintenance

Bergers, G., & Song, S. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000232 · Cited by 1,584 · see citing works

Tumors as Organs: Complex Tissues that Interface with the Entire Organism

Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,230 · see citing works

Nanomaterials for Theranostics: Recent Advances and Future Challenges

Lim, E., Kim, T., Paik, S., Haam, S., Huh, Y., & Lee, K. (2014) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,236 · see citing works

Immune infiltration in human tumors: a prognostic factor that should not be ignored

Pagès, F., Galon, J., Dieu‐Nosjean, M., Tartour, É., Sautès‐Fridman, C., & Fridman, W. H. (2009) · Oncogene · doi:10.1038/onc.2009.416 · Cited by 1,090 · see citing works

Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer

Lin, E. Y., Li, J.-F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X.-N., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1278 · Cited by 1,074 · see citing works

Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence

Chinen, A. B., Guan, C. M., Ferrer, J. R., Barnaby, S. N., Merkel, T. J., & Mirkin, C. A. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00321 · Cited by 1,030 · see citing works

The hypoxic tumour microenvironment

Petrova, V., Annicchiarico‐Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,035 · see citing works

VEGF controls endothelial-cell permeability by promoting the β-arrestin-dependent endocytosis of VE-cadherin

Gavard, J., & Gutkind, J. S. (2006) · Nature Cell Biology · doi:10.1038/ncb1486 · Cited by 1,017 · see citing works

New signals from the invasive front

Christofori, G. (2006) · Nature · doi:10.1038/nature04872 · Cited by 989 · see citing works

TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT

Tlsty, T. D., & Coussens, L. M. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100224 · Cited by 981 · see citing works

Brain metastases: epidemiology and pathophysiology

Gavrilovic, I. T., & Posner, J. B. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-8093-6 · Cited by 977 · see citing works

Matrix metalloproteinases and angiogenesis

Rundhaug, J. E. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00355.x · Cited by 962 · see citing works

Peptide-Labeled Near-Infrared Quantum Dots for Imaging Tumor Vasculature in Living Subjects

Cai, W., Shin, D., Chen, K., Gheysens, O. S., Cao, Q., Wang, S. X., Gambhir, S. S., & Chen, X. S. (2006) · Nano Letters · doi:10.1021/nl052405t · Cited by 949 · see citing works

Nanomaterials: Applications in Cancer Imaging and Therapy

Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 905 · see citing works

Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis

Popivanova, B. K., Kitamura, K., Wu, Y., Kondo, T., Kagaya, T., Kaneko, S., Oshima, M., Fujii, C., & Mukaida, N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32453 · Cited by 845 · see citing works

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841 · see citing works

In Vivo Photoacoustic Tomography of Chemicals: High-Resolution Functional and Molecular Optical Imaging at New Depths

Kim, C., Favazza, C. P., & Wang, L. V. (2010) · Chemical Reviews · doi:10.1021/cr900266s · Cited by 807 · see citing works

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets

Feitelson, M. A., Arzumanyan, A. L., Kulathinal, R. J., Blain, S. W., Holcombe, R. F., Mahajna, J. A., Marino, M., Martínez‐Chantar, M. L., Nawroth, R., Sánchez-Garcı́a, I., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.006 · Cited by 783 · see citing works

Molecular basis for sunitinib efficacy and future clinical development

Faivre, S. J., Demetri, G. D., Sargent, W., & Raymond, É. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 718 · see citing works

Metastasis: recent discoveries and novel treatment strategies.

Eccles, S., & Welch, D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60781-8 · Cited by 729 · see citing works

Hypoxia: A key regulator of angiogenesis in cancer

Liao, D., & Johnson, R. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9066-y · Cited by 720 · see citing works

Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 708 · see citing works

TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility

van Horssen, R., ten Hagen, T. L. M., & Eggermont, A. M. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-397 · Cited by 699 · see citing works

Metronomic chemotherapy: new rationale for new directions

Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 655 · see citing works

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Hu‐Lowe, D. D., Zou, H. Y., Grazzini, M. L., Hallin, M. E., Wickman, G., Amundson, K., Chen, J. H., Rewolinski, D. A., Yamazaki, S., Wu, X., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0652 · Cited by 640 · see citing works

The angiogenic switch in carcinogenesis

Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 624 · see citing works

Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy

Tatum, J. L. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000601002324 · Cited by 620 · see citing works

Nitric Oxide: Physiological Functions, Delivery, and Biomedical Applications

Andrabi, S. M., Sharma, N. S., Karan, A., Shahriar, S. M. S., Cordon, B., Ma, B., & Xie, J. (2023) · Advanced Science · doi:10.1002/advs.202303259 · Cited by 639 · see citing works

Gold Nanoparticles in Cancer Treatment

Sztandera, K., Gorzkiewicz, M., & Klajnert‐Maculewicz, B. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00810 · Cited by 608 · see citing works

The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting

Winkles, J. A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2488 · Cited by 600 · see citing works

Photodynamic Therapy—Current Limitations and Novel Approaches

Günaydın, G., Gedik, M. E., & Ayan, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.691697 · Cited by 604 · see citing works

Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis

Ardi, V. C., Kupriyanova, T. A., Deryugina, E. I., & Quigley, J. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706438104 · Cited by 603 · see citing works

Angiogenesis Analyzer for ImageJ — A comparative morphometric analysis of “Endothelial Tube Formation Assay” and “Fibrin Bead Assay”

Carpentier, G., Berndt, S., Ferratge, S., Rasband, W. S., Cuendet, M., Uzan, G., & Albanese, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-67289-8 · Cited by 603 · see citing works

Regulation of Endothelial Junctional Permeability

Vandenbroucke, E. E., Mehta, D., Minshall, R. D., & Malik, A. B. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1420.016 · Cited by 598 · see citing works

An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.

Giraudo, E., Inoue, M., & Hanahan, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422087 · Cited by 700 · see citing works

JunD Reduces Tumor Angiogenesis by Protecting Cells from Oxidative Stress

Gerald, D., Berra, E., Frapart, Y. M., Chan, D. A., Giaccia, A. J., Mansuy, D., Pouysségur, J., Yaniv, M., & Mechta-Grigoriou, F. (2004) · Cell · doi:10.1016/j.cell.2004.08.025 · Cited by 588 · see citing works

The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer

Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2013) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 581 · see citing works

In Situ Imaging of Metals in Cells and Tissues

McRae, R. L., Bagchi, P., Sumalekshmy, S., & Fahrni, C. J. (2009) · Chemical Reviews · doi:10.1021/cr900223a · Cited by 566 · see citing works

Stem cell programs in cancer initiation, progression, and therapy resistance

Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524 · see citing works

Emerging insights into the molecular and cellular basis of glioblastomaPreprint

Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 559 · see citing works

PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival

Song, S., Ewald, A. J., Stallcup, W. B., Werb, Z., & Bergers, G. (2005) · Nature Cell Biology · doi:10.1038/ncb1288 · Cited by 551 · see citing works

Significance of long chain polyunsaturated fatty acids in human health

Zárate, R., el Jaber-Vazdekis, N., Tejera, N., Pérez, J. A., & Rodríguez, C. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0153-6 · Cited by 547 · see citing works

Dual role of autophagy in hallmarks of cancer

Singh, S. S., Vats, S., Chia, A. Y.-Q., Tan, T. Z., Deng, S., Ong, M. S., Arfuso, F., Yap, C. T., Goh, B. C., Sethi, G., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0046-6 · Cited by 542 · see citing works

Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis

Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker‐Palmer, A. (2010) · Nature · doi:10.1038/nature08995 · Cited by 532 · see citing works

The tumor microenvironment and its contribution to tumor evolution toward metastasis

Lorusso, G., & Rüegg, C. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0530-8 · Cited by 527 · see citing works

Adrenergic nerves activate an angio-metabolic switch in prostate cancer

Zahalka, A. H., Arnal-Estapé, A., Maryanovich, M., Nakahara, F., Cruz, C. D., Finley, L. W. S., & Frenette, P. S. (2017) · Science · doi:10.1126/science.aah5072 · Cited by 548 · see citing works

Overcoming cancer therapeutic bottleneck by drug repurposing

Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 521 · see citing works

Transdifferentiation of glioblastoma cells into vascular endothelial cells

Soda, Y., Marumoto, T., Friedmann‐Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R. M., Kesari, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016030108 · Cited by 516 · see citing works

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo

Tian, S., Quan, H., Xie, C., Guo, H., Lü, F., Xu, Y., Li, J., & Lou, L. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01939.x · Cited by 514 · see citing works

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 508 · see citing works

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

Gotink, K. J., & Verheul, H. M. W. (2009) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 506 · see citing works

Mitochondrial Dysfunction in Cancer

Boland, M. L., Chourasia, A. H., & Macleod, K. F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00292 · Cited by 502 · see citing works

Anti-cancer chalcones: Structural and molecular target perspectives

Mahapatra, D. K., Bharti, S. K., & Asati, V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.004 · Cited by 500 · see citing works

Multimodality Molecular Imaging of Tumor Angiogenesis

Cai, W., & Chen, X. S. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045922 · Cited by 492 · see citing works

Chemokines in Cancer

Chow, M. T., & Luster, A. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0160 · Cited by 491 · see citing works

3D cell culture systems modeling tumor growth determinants in cancer target discovery

Thoma, C. R., Zimmermann, M., Agarkova, I., Kelm, J. M., & Krek, W. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.03.001 · Cited by 478 · see citing works

Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: Phenolic acids, monophenol, polyphenol, and their derivatives

Weng, C., & Yen, G. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.03.001 · Cited by 484 · see citing works

A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer

Pietras, K., & Hanahan, D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479 · see citing works

Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities

D, S. M. M., Bronte, V., & Nitti, D. (2006) · Medicinal Research Reviews · doi:10.1002/med.20092 · Cited by 480 · see citing works

Angiogenesis Inhibitors: Current Strategies and Future Prospects

Cook, K. M., & Figg, W. D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 478 · see citing works

Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5

Chen, Y., & Gorski, D. H. (2007) · Blood · doi:10.1182/blood-2007-07-104133 · Cited by 454 · see citing works

Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy

Niu, G., & Chen, X. S. (2010) · Current Drug Targets · doi:10.2174/138945010791591395 · Cited by 449 · see citing works

Metastasis mechanisms

Geiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 443 · see citing works

Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells

Ingram, D. A., Caplice, N. M., & Yöder, M. C. (2005) · Blood · doi:10.1182/blood-2005-04-1509 · Cited by 442 · see citing works

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin

Phung, T. L., Ziv, K., Dabydeen, D. A., Eyiah-Mensah, G., Riveros, M., Perruzzi, C. A., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 439 · see citing works

The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents

Tabernero, J. M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0404 · Cited by 438 · see citing works

Exploring the Role of RGD-Recognizing Integrins in Cancer

Nieberler, M., Reuning, U., Reichart, F., Notni, J., Wester, H., Schwaiger, M., Weinmüller, M., Räder, A. F. B., Steiger, K., & Kessler, H. (2017) · Cancers · doi:10.3390/cancers9090116 · Cited by 429 · see citing works

Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer

Kong, W. W., He, L., Richards, E. J., Challa, S., Cx, X., Permuth‐Wey, J., Lancaster, J., Coppola, D., Sellers, T. A., Djeu, J. Y., et al. (2013) · Oncogene · doi:10.1038/onc.2012.636 · Cited by 422 · see citing works

CXC chemokines: the regulatory link between inflammation and angiogenesis

Romagnani, P., Lasagni, L., Annunziato, F., Serio, M., & Romagnani, S. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.02.006 · Cited by 410 · see citing works

Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer.

Johansen, J. S. (2006) · PubMed · Cited by 404 · see citing works

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer

Haibe, Y., Kreidieh, M., Hajj, H. E., Khalifeh, I. M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 410 · see citing works

Understanding the biology of angiogenesis: Review of the most important molecular mechanisms

Otrock, Z. K., Mahfouz, R. A., Makarem, J. A., & Shamseddine, A. I. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.04.001 · Cited by 390 · see citing works

Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1

Lin, B., Song, X., Yang, D., Dongsheng, B., Yao, Y., & Lu, N. (2018) · Gene · doi:10.1016/j.gene.2018.02.026 · Cited by 387 · see citing works

The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases

Cauwe, B., den Steen, P. E. V., & Opdenakker, G. (2007) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230701340019 · Cited by 384 · see citing works

Survivin: A new target for anti-cancer therapy

Ryan, B. M., O’Donovan, N., & Duffy, M. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.05.003 · Cited by 378 · see citing works

Jekyll and Hyde: the role of the microenvironment on the progression of cancer

Allen, M. D., & Jones, J. L. (2010) · The Journal of Pathology · doi:10.1002/path.2803 · Cited by 370 · see citing works

Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis

Langley, R. R., & Fidler, I. J. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0027 · Cited by 368 · see citing works

Biological applications of microfluidic gradient devices

Kim, S., Kim, H. J., & Jeon, N. L. (2010) · Integrative Biology · doi:10.1039/c0ib00055h · Cited by 366 · see citing works

Immune cells as mediators of solid tumor metastasis

DeNardo, D. G., Johansson, M., & Coussens, L. M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9100-0 · Cited by 370 · see citing works

MicroRNAs and the hallmarks of cancer

Dalmay, T., & Edwards, D. R. (2006) · Oncogene · doi:10.1038/sj.onc.1209911 · Cited by 368 · see citing works

Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics

Gong, F., Yang, N., Wang, X., Zhao, Q., Chen, Q., Liu, Z., & Cheng, L. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100851 · Cited by 365 · see citing works

Hyperprogressive disease: recognizing a novel pattern to improve patient management

Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 360 · see citing works

Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development

Lichtenberger, B. M., Tan, P. K., Niederleithner, H., Ferrara, N., Petzelbauer, P., & Sibilia, M. C. (2010) · Cell · doi:10.1016/j.cell.2009.12.046 · Cited by 357 · see citing works

Cancer and Angiogenesis

Miller, F., & Singh, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-28558-0_2 · Cited by 1 · see citing works

Angiogenesis and the Tumor Microenvironment

Murphy, J. F. (2025) · Springer eBooks · doi:10.1007/978-3-032-00761-2_87

Anti‐angiogenesis and metastasis: a tumour and stromal cell alliance

Moserle, L., & Casanovas, O. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12018 · Cited by 66 · see citing works

Tumours can adapt to anti-angiogenic therapy depending on the stromal context: Lessons from endothelial cell biology

van Kempen, L. C. L. T., & Leenders, W. P. J. (2005) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2005.10.003 · Cited by 31 · see citing works

Influence of the Tumor Microenvironment on Angiogenesis

Payne, S. J., & Jones, J. L. (2011) · Future Oncology · doi:10.2217/fon.11.13 · Cited by 29 · see citing works